The identification of mutations in patients with cardiomyopathies is pivotal to establish diagnosis and treatment and together with biomarkers of myocardial failure, such as brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), can represent the starting point for implementing a precision medicine approach. Here, NPPB is linked to cardiomyopathy.